BR112021026439A2 - Vacina para febre suína africana - Google Patents
Vacina para febre suína africanaInfo
- Publication number
- BR112021026439A2 BR112021026439A2 BR112021026439A BR112021026439A BR112021026439A2 BR 112021026439 A2 BR112021026439 A2 BR 112021026439A2 BR 112021026439 A BR112021026439 A BR 112021026439A BR 112021026439 A BR112021026439 A BR 112021026439A BR 112021026439 A2 BR112021026439 A2 BR 112021026439A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- peptides
- swine fever
- african swine
- animal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
vacina para febre suína africana. peptídeos preditos serem imunogênicos contra o vírus da febre suína africana (asfv) e as composições de vacina que incluem os peptídeos são aqui descritos. em algumas modalidades, essas composições compreendem ou consistem em um ou mais peptídeos que compreendem a sequência de aminoácidos descrita nas seq id nos: 2 a 2273. em outras modalidades, as composições compreen-dem vetores virais ou células hospedeiras, ou combinações dos mes-mos, que compreendem um ou mais peptídeos. em outras modalida-des, as composições compreendem moléculas de ácido nucleico que compreendem um ou mais peptídeos. as composições descritas po-dem incluir um ou mais componentes adicionais, tais como, mas não se limitando a, um veículo, um adjuvante, um agente terapêutico adici-onal ou combinações dos mesmos. recipientes e kits que compreen-dem as composições são descritos. os usos das composições podem incluir a administração a um animal para induzir uma resposta imune no animal ou para imunizar o animal contra asfv. a administração pode ser realizada usando um ou mais dos vários métodos aqui descri-tos, tais como administração intramuscular ou intranasal.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962868483P | 2019-06-28 | 2019-06-28 | |
US201962941381P | 2019-11-27 | 2019-11-27 | |
PCT/US2020/039846 WO2020264312A1 (en) | 2019-06-28 | 2020-06-26 | African swine fever vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021026439A2 true BR112021026439A2 (pt) | 2022-02-15 |
Family
ID=71728905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021026439A BR112021026439A2 (pt) | 2019-06-28 | 2020-06-26 | Vacina para febre suína africana |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220105170A1 (pt) |
EP (1) | EP3990012A1 (pt) |
JP (1) | JP2022538673A (pt) |
KR (1) | KR20220031028A (pt) |
CN (1) | CN113454102A (pt) |
AU (1) | AU2020304652A1 (pt) |
BR (1) | BR112021026439A2 (pt) |
CA (1) | CA3145228A1 (pt) |
MX (1) | MX2021015465A (pt) |
WO (1) | WO2020264312A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113845572B (zh) * | 2020-08-26 | 2023-11-21 | 中国农业科学院兰州兽医研究所 | 一类促进猪机体产生广谱获得性免疫应答的多肽及其应用 |
CN114621321B (zh) * | 2020-08-26 | 2024-04-05 | 中国农业科学院兰州兽医研究所 | 一类促进猪机体产生广谱性免疫应答的多肽及其应用 |
CN114044806B (zh) * | 2020-08-26 | 2023-10-24 | 中国农业科学院兰州兽医研究所 | 一类促进猪机体产生广谱性免疫应答的多肽及其应用 |
CN112724203A (zh) * | 2020-12-30 | 2021-04-30 | 郑州大学 | 一种非洲猪瘟病毒p54蛋白抗原表位肽及其应用 |
CN113061588B (zh) * | 2021-05-20 | 2023-08-01 | 军事科学院军事医学研究院军事兽医研究所 | 缺失i226r基因的非洲猪瘟病毒减毒株及其活疫苗 |
CN113755505B (zh) * | 2021-09-30 | 2023-05-02 | 绵阳市游仙区创新科技产业技术研究院 | 治疗和/或预防非洲猪瘟病毒的疫苗及其制备方法 |
WO2024031045A2 (en) * | 2022-08-04 | 2024-02-08 | Malcolm Thomas | Dominant negative antigen approach for prophylactic and post-infection treatment of swine against african swine fever virus |
US11969453B2 (en) | 2023-06-14 | 2024-04-30 | Nae Woi Korea., Ltd. | Horseradish and cinnamon mixed extract composition for suppression of avian viral epidemic diseases |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1897958B (zh) | 2003-12-24 | 2011-02-02 | 特拉维夫大学拉玛特有限公司 | 从天然肉桂提取物中获得的抗病毒制剂 |
US8008268B2 (en) * | 2006-07-25 | 2011-08-30 | Merial Limited | Vaccines against vesicular stomatitis |
EP2771349B1 (en) * | 2011-09-16 | 2020-02-26 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
ES2401276B1 (es) * | 2011-10-04 | 2014-02-19 | Fundació Centre De Recerca En Sanitat Animal | Utilización de una construcción genica y/o peptídica para la fabricación de una vacuna para la prevención y/o tratamiento de la infección causada por el virus de la peste porcina africana (vppa). |
CN103805615A (zh) * | 2014-02-19 | 2014-05-21 | 孙洁 | 密码子优化的非洲猪瘟病毒p54基因、其核酸疫苗及应用 |
US10279031B2 (en) | 2016-05-11 | 2019-05-07 | Phibro Animal Health Corporation | Composition comprising antigens and a mucosal adjuvant and a method for using |
-
2020
- 2020-06-26 EP EP20743434.1A patent/EP3990012A1/en active Pending
- 2020-06-26 MX MX2021015465A patent/MX2021015465A/es unknown
- 2020-06-26 KR KR1020227002627A patent/KR20220031028A/ko unknown
- 2020-06-26 CA CA3145228A patent/CA3145228A1/en active Pending
- 2020-06-26 JP JP2021578242A patent/JP2022538673A/ja active Pending
- 2020-06-26 AU AU2020304652A patent/AU2020304652A1/en active Pending
- 2020-06-26 BR BR112021026439A patent/BR112021026439A2/pt unknown
- 2020-06-26 WO PCT/US2020/039846 patent/WO2020264312A1/en active Application Filing
- 2020-06-26 CN CN202080001395.0A patent/CN113454102A/zh active Pending
-
2021
- 2021-12-17 US US17/554,232 patent/US20220105170A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20220031028A (ko) | 2022-03-11 |
CN113454102A (zh) | 2021-09-28 |
US20220105170A1 (en) | 2022-04-07 |
WO2020264312A1 (en) | 2020-12-30 |
CA3145228A1 (en) | 2020-12-30 |
MX2021015465A (es) | 2022-03-11 |
AU2020304652A1 (en) | 2022-02-24 |
JP2022538673A (ja) | 2022-09-05 |
EP3990012A1 (en) | 2022-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021026439A2 (pt) | Vacina para febre suína africana | |
CL2021000636A1 (es) | Vacuna contra el virus de la peste porcina africana | |
EA202192570A1 (ru) | Иммуногенные композиции и вакцины, содержащие пептиды и белки вируса африканской чумы свиней, и их применение | |
BR112022014808A2 (pt) | Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2 | |
BR112018011711A2 (pt) | peptídeos de direcionamento para direcionar virus adeno-associados (aav) | |
BR112021005769A2 (pt) | proteínas de ligação a dll3 e métodos de uso | |
CL2020000295A1 (es) | Métodos de terapia génica del factor viii (fviii) | |
Del Campo et al. | OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes | |
BR112019018307A2 (pt) | Plataforma para identificação de peptídeos imunogênicos baseada em população | |
CY1115749T1 (el) | Κυκλοϊος χοιρων, νουκλεϊνικα οξεα, πολυπεπτιδια και εμβολια | |
BR112017019140A2 (pt) | métodos de tratamento de câncer usando células t ativadas | |
BR112022016550A2 (pt) | Proteínas de ligação a flt3 e métodos de uso | |
EE200100203A (et) | Meetod immuunvastuse indutseerimiseks polüpeptiidse antigeeni vastu ja rakuga seotud polüpeptiidse antigeeni mahasurumiseks loomorganismil, selle meetodi kasutamine eesnäärme- ja rinnavähi raviks ning immunogeenne kompositsioon | |
BR112019005511A2 (pt) | vetores de adenovírus canino | |
BRPI0815578B8 (pt) | peptídeos, agentes farmacêuticos compreendendo os mesmos, métodos in vitro para induzir uma célula apresentadora de antígeno, usos dos referidos peptídeos, e vacina | |
BR112014014078A8 (pt) | Composições compreendendo constructos genéticos il-12 aperfeiçoados e vacinas, imunoterapêuticos e métodos de usar os mesmos | |
BR112022016992A2 (pt) | Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2 | |
ES2546288T3 (es) | Método de purificación de complejos de proteínas de choque térmico | |
BR112022024063A2 (pt) | Polipeptídeos de coronavírus 2 da síndrome respiratória aguda grave (sars-cov-2) e usos dos mesmos para fins de vacina | |
BR112022026580A2 (pt) | Composições e métodos para induzir uma resposta imune contra coronavírus | |
Cox et al. | Non‐lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication | |
CL2022002416A1 (es) | Vacuna | |
BR112023021654A2 (pt) | Vacina contra vírus | |
AR051853A1 (es) | Vacuna para aumentar el crecimiento basada en epitopes neutralizantes | |
BR112022017032A2 (pt) | Composições compreendendo ltb e antígenos patogênicos, e uso das mesmas. |